Kaspofungin Teva

Caspofungin, the active ingredient in Kaspofungin Teva, is an echinocandin presented as an intravenous solution for intravenous use. It treats serious fungal infections such as invasive candidiasis, esophageal candidiasis, and invasive aspergillosis in immunocompromised patients.

GNH USA supplies Kaspofungin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Caspofungin is an echinocandin antifungal that targets the fungal cell wall.

- Invasive candidiasis: provides effective therapy for bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection in patients with esophageal involvement. - Invasive aspergillosis: used as treatment for severe Aspergillus infections in high‑risk patients.

Caspofungin may cause a range of adverse reactions.

Common Side Effects: - Fever: transient elevation of body temperature. - Chills: shaking sensations often accompanying infusion. - Nausea: mild to moderate upset stomach. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including rash, bronchospasm, or anaphylaxis. - Hepatic failure: marked elevation of liver enzymes or jaundice. - Renal impairment: acute kidney injury or worsening of pre‑existing renal disease.

Caspofungin requires careful monitoring and specific handling precautions.

- Monitor liver function: obtain baseline and periodic LFTs during therapy. - Assess renal function: evaluate creatinine clearance before and during treatment. - Evaluate for hypersensitivity: discontinue immediately if severe allergic reaction occurs. - Use caution in pre‑existing hepatic disease: adjust therapy based on clinical judgment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Caspofungin can interact with several drug classes.

Major Interactions (Avoid): - Rifampin: strong CYP inducers may reduce caspofungin exposure. - Ketoconazole: potent CYP3A4 inhibitors may increase caspofungin levels. - Other echinocandins (e.g., micafungin): concurrent use may lead to additive toxicity.

Moderate Interactions (Monitor Closely): - Tacrolimus: immunosuppressants may require dose adjustment. - Aminoglycosides: nephrotoxic agents warrant renal function monitoring. - Azole antifungals: combined use may increase risk of hepatic adverse events.